Dario Graceffa

Rome, 00144, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Guselkumab Every 4 Weeks as a Real-World Therapeutic Option for Psoriatic Arthritis Patients at High Risk of Joint Damage.

Guselkumab Every 4 Weeks as a Real-World Therapeutic Option for Psoriatic Arthritis Patients at High Risk of Joint Damage.

Journal: Clinics and practice

Published: July 08, 2026

Long-Term Effectiveness of Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: A 104-week Real-World Clinical and Ultrasound Study.

Long-Term Effectiveness of Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: A 104-week Real-World Clinical and Ultrasound Study.

Journal: Psoriasis (Auckland, N.Z.)

Published: March 31, 2026

Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort.

Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort.

Journal: The Journal of dermatological treatment

Published: January 23, 2026

Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the Legs.

Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the Legs.

Journal: Clinics and practice

Published: November 19, 2025

Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms.

Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms.

Journal: Drugs in context

Published: May 06, 2025

Brodalumab Efficacy in Psoriasis Patients with Inadequate Response to IL-23 or IL-12/23 Inhibitors: Multicenter Italian Retrospective Analysis - IL PSO (Italian Landscape Psoriasis).

Brodalumab Efficacy in Psoriasis Patients with Inadequate Response to IL-23 or IL-12/23 Inhibitors: Multicenter Italian Retrospective Analysis - IL PSO (Italian Landscape Psoriasis).

Journal: Dermatology practical & conceptual

Published: March 06, 2025

Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study - IL PSO (Italian Landscape Psoriasis).

Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study - IL PSO (Italian Landscape Psoriasis).

Journal: The Journal of dermatological treatment

Published: February 06, 2025

BRodalumab effectiveness in psoriatic patients that experienced anti-IL17 Intra-Class failure: a multicentre, retrospective study (BRIC - Study) IL-PSO (Italian Landscape Psoriasis).

BRodalumab effectiveness in psoriatic patients that experienced anti-IL17 Intra-Class failure: a multicentre, retrospective study (BRIC - Study) IL-PSO (Italian Landscape Psoriasis).

Journal: Clinical and experimental dermatology

Published: January 17, 2025

CORONATE: A Novel Questionnaire to Assess the Long-Term Impact of Psoriasis on Patients' Lives.

CORONATE: A Novel Questionnaire to Assess the Long-Term Impact of Psoriasis on Patients' Lives.

Journal: Dermatology practical & conceptual

Published: January 17, 2025

Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients-IL PSO (Italian Landscape Psoriasis).

Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients-IL PSO (Italian Landscape Psoriasis).

Journal: Journal of clinical medicine

Published: December 31, 2024

Psoriasis and Emotional Dysregulation: A Multicenter Analysis of Psychodermatology Outcomes.

Psoriasis and Emotional Dysregulation: A Multicenter Analysis of Psychodermatology Outcomes.

Journal: Dermatology practical & conceptual

Published: December 27, 2024

Lichen planus-like reaction following bimekizumab treatment in a psoriatic patient with HCV infection.

Lichen planus-like reaction following bimekizumab treatment in a psoriatic patient with HCV infection.

Journal: European journal of dermatology : EJD

Published: November 26, 2024

Showing 1-12 of 55

Last Updated: 09/26/2026